Crinetics price target raised to $50 from $42 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Crinetics to $50 from $42 and keeps a Buy rating on the shares. The firm says that with key catalysts upcoming and a “relatively inexpensive” valuation for biotech, it raised the price target given the “breadth of opportunities” for the company. It sees significant upside above even the new target.